trending Market Intelligence /marketintelligence/en/news-insights/trending/z1rFEjtMoMQ76MGsH33nlw2 content esgSubNav
In This List

ImmunoPrecise to acquire U-Protein for €6.8M

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


ImmunoPrecise to acquire U-Protein for €6.8M

ImmunoPrecise Antibodies Ltd. acquired all of U-Protein Express BV's issued and outstanding shares for €6.8 million.

ImmunoPrecise will pay €2.7 million in cash, issue €2 million of its shares and settle the remaining €2 million over a three-year period, either in cash or stock.

Martin Hessing, one of the principal shareholders of U-Protein, will join the ImmunoPrecise board.

ImmunoPrecise recently upsized a private placement to use the proceeds for the acquisition of U-Protein.